Author: Paragas, Jason; Blatt, Lawrence M.; Hartmann, Chris; Huggins, John W.; Endy, Tim P.
Title: Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models Cord-id: o8ygdd14 Document date: 2005_2_15
ID: o8ygdd14
Snippet: Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC(50) of 0.001 μg/ml, a clinically achievable level. Further
Document: Preliminary data examining interferon alfacon1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon1 inhibited the generation of CPE in a dose-dependent manner with an IC(50) of 0.001 μg/ml, a clinically achievable level. Furthermore, interferon alfacon1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon1 against SARS-CoV suggests continued evaluation of interferon alfacon1 as a therapeutic treatment for patients infected with SARS-CoV.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adaptive immunity innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adaptive immunity innate modulate: 1
Co phrase search for related documents, hyperlinks ordered by date